LEUCOVORIN CALCIUM Drug Patent Profile
✉ Email this page to a colleague
When do Leucovorin Calcium patents expire, and what generic alternatives are available?
Leucovorin Calcium is a drug marketed by Hospira, Abic, Abraxis Pharm, Elkins Sinn, Fresenius Kabi Usa, Hainan Poly, Hikma, Kindos, Novast Labs, Pharmachemie, Pharmachemie Usa, Teva Parenteral, Teva Pharms Usa, Ani Pharms, Barr, Epic Pharma Llc, Leading, Par Pharm, Xanodyne Pharm, Am Regent, Mylan Labs Ltd, Sagent Pharms, and Sagent Pharms Inc. and is included in forty-eight NDAs.
The generic ingredient in LEUCOVORIN CALCIUM is leucovorin calcium. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the leucovorin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Leucovorin Calcium
A generic version of LEUCOVORIN CALCIUM was approved as leucovorin calcium by HIKMA on September 14th, 1987.
Summary for LEUCOVORIN CALCIUM
US Patents: | 0 |
Applicants: | 23 |
NDAs: | 48 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 476 |
Patent Applications: | 5,849 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LEUCOVORIN CALCIUM |
DailyMed Link: | LEUCOVORIN CALCIUM at DailyMed |
Recent Clinical Trials for LEUCOVORIN CALCIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fudan University | Phase 3 |
Arcus Biosciences, Inc. | Phase 1/Phase 2 |
Jonsson Comprehensive Cancer Center | Phase 1/Phase 2 |
Pharmacology for LEUCOVORIN CALCIUM
Drug Class | Folate Analog |